Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Intensity Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FIRST PATIENTS DOSED IN SWITZERLAND SHELTON, CONN., JULY 15, 2026 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. ("INTENSITY"OR "THE COMPANY") (NASDAQ: INTS), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, TODAY ANNOUNCES THAT NEW PATIENTS HAVE BEEN ADMINISTERED INT230-6 IN THE INVINCIBLE-4 STUDY IN SWITZERLAND.

INTENSITY THERAPEUTICS, INC. RESTARTS PATIENT TREATMENT IN THE RANDOMIZED, PRESURGICAL TRIPLE NEGATIVE BREAST CANCER PHASE 2 CLINICAL TRIAL (INVINCIBLE-4 STUDY)

LATE-STAGE CLINICAL STUDIES ADVANCING IN SOFT TISSUE SARCOMA AND PRESURGICAL TRIPLE-NEGATIVE BREAST CANCER OVER 200 PATIENTS ENROLLED IN COMPLETED INT230-6 STUDIES WITH A PEER-REVIEWED PAPER PUBLISHED ACTIVE STRATEGIC PARTNERING INITIATIVES SUPPORTED BY MATURING INT230-6 CLINICAL AND REGULATORY PROFILE STRENGTHENED BALANCE SHEET SUPPORTING DISCIPLINED CLINICAL DEVELOPMENT STRATEGY SHELTON, CONN., JULY 1, 2026 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. ("INTENSITY" OR "THE COMPANY") (NASDAQ: INTS), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, TODAY PROVIDES A MID-YEAR UPDATE HIGHLIGHTING THE COMPANY'S LATE-STAGE DEVELOPMENT PROGRAMS AND GROWING STRATEGIC PARTNERING FOCUS FOR INT230-6.

INTENSITY THERAPEUTICS PROVIDES MID-YEAR UPDATE HIGHLIGHTING LATE-STAGE DEVELOPMENT PROGRAMS AND STRATEGIC PARTNERING OPPORTUNITIES FOR INT230-6

COMPANY RECEIVES THE CANCER TREATMENT TECHNOLOGY INNOVATOR OF THE YEAR AWARD SHELTON, CONN., MAY 14, 2026 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC., (NASDAQ: INTS) ("INTENSITY" OR THE "COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF PROPRIETARY CANCER THERAPIES USING ITS NON-COVALENT, DRUG-CONJUGATION TECHNOLOGY THAT CREATES DRUG PRODUCTS DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS, ANNOUNCES IT HAS BEEN NAMED A WINNER OF THE 2026 GHP MAGAZINE HEALTHCARE & PHARMACEUTICAL AWARDS AS THE CANCER TREATMENT TECHNOLOGY INNOVATOR OF THE YEAR 2026  USA AWARD RECIPIENT.

INTENSITY THERAPEUTICS RECOGNIZED WITH GHP MAGAZINE'S 2026 HEALTHCARE & PHARMACEUTICAL AWARD

CASH AND CASH EQUIVALENTS OF $10.2 MILLION AS OF MARCH 31, 2026 FAVORABLE EFFICACY AND SAFETY REPORTED IN A SMALL SAMPLE OF TRIPLE NEGATIVE BREAST CANCER ("TNBC") PATIENTS RECEIVING INT230-6 PRIOR TO THE STANDARD OF CARE ("SOC") COMPARED TO SOC ALONE IN THE INVINCIBLE-4 STUDY (AS DEFINED BELOW) APPROVAL TO RESUME ENROLLMENT OBTAINED IN THE INVINCIBLE-4 STUDY; PLANS TO RESUME ENROLLMENT IN THE SECOND QUARTER OF 2026 DECISION TO RESUME ENROLLMENT IN A LIMITED NUMBER OF U.S. SITES IN THE INVINCIBLE-3 STUDY (AS DEFINED BELOW) BY THE THIRD QUARTER OF 2026 SHELTON, CONN., MAY 7, 2026 /PRNEWSWIRE/ --INTENSITY THERAPEUTICS, INC. ("INTENSITY" OR "THE COMPANY") (NASDAQ: INTS), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.

INTENSITY THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

COMPANY RECEIVES THE PLATINUM AWARD FOR INNOVATOR IN BIOTECH SOLUTIONS CATEGORY SHELTON, CONN., APRIL 15, 2026 /PRNEWSWIRE/ --INTENSITY THERAPEUTICS, INC., (NASDAQ: INTS) ("INTENSITY" OR THE "COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF PROPRIETARY CANCER THERAPIES USING ITS NON-COVALENT, DRUG-CONJUGATION TECHNOLOGY THAT CREATES DRUG PRODUCTS DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS, ANNOUNCES IT HAS BEEN NAMED A WINNER OF THE 2026 PINNACLE AWARDS FOR HEALTHCARE FOR ITS INTRATUMORAL INJECTION PLATFORM AND LEAD DRUG CANDIDATE INT230-6.

INTENSITY THERAPEUTICS RECOGNIZED WITH PINNACLE AWARD FOR EXCELLENCE IN HEALTHCARE INNOVATION

RAISED OVER $20 MILLION IN GROSS PROCEEDS IN 2025 AND HELD $11.9 MILLION IN CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2025, WITH A CASH RUNWAY INTO THE SECOND QUARTER OF 2027 IT-01 STUDY MANUSCRIPT OF INT230-6 USED ALONE IN 64 REFRACTORY METASTATIC CANCER PATIENTS PUBLISHED IN THE LANCET'S JOURNAL EBIOMEDICINE, INCLUDING DATA FOR DISEASE CONTROL RATE, OVERALL SURVIVAL, IMMUNE ACTIVATION, ABSCOPAL EFFECTS, TUMOR NECROSIS, DOSE RANGING, AND SAFETY FAVORABLE EFFICACY AND SAFETY REPORTED IN A SMALL SAMPLE OF TRIPLE NEGATIVE BREAST CANCER ("TNBC") PATIENTS RECEIVING INT230-6 PRIOR TO THE STANDARD OF CARE ("SOC") COMPARED TO SOC ALONE IN THE INVINCIBLE-4 STUDY SHELTON, CONN., MARCH 27, 2026 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. ("INTENSITY" OR "THE COMPANY") (NASDAQ: INTS), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, ANNOUNCES 2025 YEAR-END FINANCIAL RESULTS AND HIGHLIGHTS, AND PROVIDES A CORPORATE UPDATE.

INTENSITY THERAPEUTICS REPORTS 2025 YEAR END FINANCIAL RESULTS AND HIGHLIGHTS, AND PROVIDES CORPORATE UPDATE

NEW US PATENT 12,496,345 STRENGTHENS THE EXISTING PORTFOLIO PATENTS NOW GRANTED IN 41 COUNTRIES PROTECT THE COMPANY'S NOVEL INTRATUMORAL TECHNOLOGY, INCLUDING LEAD COMPOUND INT230-6 SHELTON, CONN., MARCH 24, 2026 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC., (NASDAQ: INTS) ("INTENSITY" OR THE "COMPANY"), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF PROPRIETARY CANCER THERAPIES USING ITS NON-COVALENT, DRUG-CONJUGATION TECHNOLOGY THAT CREATES DRUG PRODUCTS DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS, PROVIDED AN UPDATE ON ITS PATENT PORTFOLIO INCLUDING THE RECENT ISSUANCE IN DECEMBER 2025 OF A NEW US PATENT IN THE U.S., US PATENT NUMBER 12,496,345, ENTITLED "A METHOD OF TREATING CANCER".

INTENSITY THERAPEUTICS STRENGTHENS IP PORTFOLIO WITH ISSUANCE OF NEW PATENT IN THE US

PRELIMINARY OBSERVATIONS OF THE INVINCIBLE-4 STUDY TO DATE SHOWED THAT FIVE (5) OUT OF SEVEN (7) PATIENTS (71.4%) WHO RECEIVED INT230-6 PRIOR TO STANDARD OF CARE ("SOC") ("COHORT A") ACHIEVED A PATHOLOGICAL COMPLETE RESPONSE ("PCR") WHEREAS TWO (2) OUT OF SIX (6) (33%) PATIENTS IN THE SOC ARM ALONE ("COHORT B") ACHIEVED A PCR, WITH ONE PATIENT STILL TO BE EVALUATED.  FORTY-FOUR PERCENT (44%) FEWER GRADE 3 OR HIGHER ADVERSE EVENTS ("AES") WERE OBSERVED IN COHORT A COMPARED TO COHORT B.

INTENSITY THERAPEUTICS, INC. PROVIDES UPDATE ON THE PHASE 2 PRESURGICAL TRIPLE-NEGATIVE BREAST CANCER INVINCIBLE-4 STUDY

SHELTON, CONN., MARCH 6, 2026 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. ("INTENSITY" OR "THE COMPANY") (NASDAQ: INTS), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, TODAY ANNOUNCED THAT IT HAS RECEIVED FORMAL NOTICE FROM THE LISTINGS QUALIFICATIONS STAFF OF THE NASDAQ STOCK MARKET LLC ("NASDAQ") THAT THE COMPANY HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULE 5550(A)(2), WHICH REQUIRES A MINIMUM BID PRICE OF $1.00 PER SHARE.

INTENSITY THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE REQUIREMENT

INTENSITY'S COMMON STOCK IS EXPECTED TO BEGIN TRADING ON A POST-SPLIT ADJUSTED BASIS ON FEBRUARY 19, 2026 SHELTON, CONN., FEB. 13, 2026 /PRNEWSWIRE/ -- INTENSITY THERAPEUTICS, INC. ("INTENSITY" OR "THE COMPANY") (NASDAQ: INTS), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL INTRATUMORAL CANCER THERAPIES THAT ARE DESIGNED TO KILL TUMORS AND INCREASE IMMUNE SYSTEM RECOGNITION OF CANCERS USING ITS PROPRIETARY NON-COVALENT CONJUGATION TECHNOLOGY, TODAY ANNOUNCED THAT THE BOARD OF DIRECTORS OF THE COMPANY APPROVED A 1-FOR-25 REVERSE STOCK SPLIT (THE "REVERSE SPLIT") OF THE COMPANY'S COMMON STOCK.

Intensity Therapeutics, Inc.

INTS

Price

Financial Reports

No items found.

Press Releases

Intensity Therapeutics, Inc.

INTS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

INTS